mdlinx mdlinx
Latest (41) Full Text Articles (1263) Focus on Schizophrenia Article Summary

Pulsed radiofrequency in peripheral posttraumatic neuropathic pain: A double blind sham controlled randomized clinical trial
Scandinavian Journal of Pain, 07/11/2012

Akural E et al. – Pulsed radiofrequency treatment (PRF) was well tolerated, but this study failed to show efficacy of PRF over sham treatment for peripheral posttraumatic neuropathic pain (NP).

Methods
  • 45 patients with peripheral posttraumatic NP in their upper or lower limb were randomly assigned to receive PRF or sham treatment to the injured peripheral nerve(s) causing peripheral posttraumatic NP.
  • Only patients whose pain intensity was at least 5 on numerical rating scale (NRS) 0–10 and who had suffered from their NP for at least 6months were included.
  • All patients had dynamic mechanical allodynia or pinprick hyperalgesia in their painful area.
  • They had achieved temporary pain relief of at least 50% with a local nerve block performed at a previous visit.
  • The primary efficacy variable was the difference in 3–day mean pain intensity score from the baseline to 3months.
  • Other variables included response defined as ≥30% reduction in mean pain intensity at 3months compared to baseline, Neuropathic Pain Scale (NPS) results, health related quality of life (SF–36) and adverse effects.
  • The skin was anesthetized with 1% lidocaine.
  • A radiofrequency needle was introduced through the skin, and then guided to a SMK cannula (52, 100 or 144mm depending on the target nerve) with 4 or 5mm active tip (SMK–C5–4, SMK–C10–5, SMK–C15–5, Radionics, Burlington, MA, USA).
  • The nerve was located accurately by stimulating at 50Hz (threshold <0.5V).
  • Sham treatment or PRF was applied for 120s 1–4 times at each treatment point (Radionics, Burlington, MA, USA).
  • The total treatment time was up to 8min.
  • Both patients and clinicians were blinded during the whole treatment and follow–up period.

Results
  • Forty–three patients were included in the analyses.
  • There was no statistically significant difference between PRF and sham treatment for the primary outcome efficacy variable.
  • Seven patients (3 in PRF group and 4 in sham treatment group) achieved ≥30% pain relief (difference between groups was not significant).
  • There was no statistically significant difference in the NPS or any dimension of SF–36 between the treatments.
  • Eighteen patients reported adverse effects.
  • They were mild and did not necessitate any treatment.
  • Transient pain was reported by 17 patients, local irritation by 5 patients and local inflammation by 1 patient.
  • There was no significant difference between the groups in the presence of adverse effects.

► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Psychiatry

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Psychiatry Articles

Last month's top read Top Articles of 2012

1 Nidotherapy for people with schizophrenia Cochrane Reviews, April 11, 2013    Evidence Based Medicine    Clinical Article

2 Newly diagnosed depression is associated with increased beta-thromboglobulin levels and increased expression of platelet activation markers and platelet derived CD40-CD40L Journal of Psychiatric Research, April 12, 2013    Clinical Article

3 Use of asenapine in clinical practice for the management of bipolar mania Journal of Psychopharmacology, March 29, 2013    Review Article    Clinical Article

4 Risperidone, quetiapine, and olanzapine adjunctive treatments in major depression with psychotic features: a comparative study Full Text Neuropsychiatric Disease and Treatment, April 18, 2013    Free full text    Clinical Article

5 Buprenorphine augmentation in the treatment of refractory obsessive-compulsive disorder Therapeutic Advances in Psychopharmacology, March 1, 2013    Clinical Article

6 Efficacy and mood conversion rate during long-term fluoxetine v. lithium monotherapy in rapid- and non-rapid-cycling bipolar II disorder The British Journal of Psychiatry, April 3, 2013    Clinical Article

7 The association between low vitamin D and depressive disorders Full Text Molecular Psychiatry, April 10, 2013    Free full text    Clinical Article

8 A randomised, controlled trial of a dietary intervention for adults with major depression (the SMILES trial): study protocol Full Text BMC Psychiatry, April 19, 2013    Free full text    Clinical Article

9 An open trial of pregabalin as an acute and maintenance adjunctive treatment for outpatients with treatment resistant bipolar disorder Journal of Affective Disorders, March 22, 2013    Clinical Article

10 Add-on fluvoxamine treatment for schizophrenia: an updated meta-analysis of randomized controlled trials European Archives of Psychiatry and Clinical Neuroscience, April 22, 2013    Evidence Based Medicine    Clinical Article

11 Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: A 12-month, double-blind, noninferiority study Schizophrenia Research, April 16, 2013    Clinical Article

12 Rapid Effects of Deep Brain Stimulation for Treatment-Resistant Major Depression Biological Psychiatry, April 8, 2013    Clinical Article

13 Reboxetine Treatment for Autistic Spectrum Disorder of Pediatric Patients With Depressive and Inattentive/Hyperactive Symptoms: An Open-Label Trial Clinical Neuropharmacology, April 5, 2013    Clinical Article

14 Lower CSF Interleukin-6 predicts future depression in a population-based sample of older women followed for 17 years Brain, Behavior, and Immunity, April 19, 2013    Clinical Article
Exclusive Author Commentary

15 Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression Human Psychopharmacology: Clinical and Experimental, March 28, 2013    Clinical Article

16 Cortisol Levels and Risk for Psychosis: Initial Findings from the North American Prodrome Longitudinal Study Biological Psychiatry, April 5, 2013    Clinical Article

17 Therapeutic effects of vitamin D as adjunctive therapy to fluoxetine in patients with major depressive disorder Australian and New Zealand Journal of Psychiatry, March 6, 2013    Clinical Article

18 Additional ECT increases BDNF-levels in patients suffering from major depressive disorders compared to patients treated with citalopram only Journal of Psychiatric Research, April 15, 2013    Clinical Article

19 Efficacy of vitamin C as an adjunct to fluoxetine therapy in pediatric major depressive disorder: a randomized, double-blind, placebo-controlled pilot study Full Text Nutrition Journal, March 14, 2013    Free full text    Clinical Article

20 Efficiacy of Melatonin in Chronic Tension Type Headache Patients and Effects on Anxiety and Depression Full Text Journal of Neurological Sciences (Turkish), April 1, 2013    Free full text    Clinical Article

Indexed Journals in Psychiatry : Current Psychiatry, Bipolar Disorders, American Journal of Psychiatry, Addictionmore

Other Topics in Psychiatry

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow Us
Facebook

Receive free subspecialty
"5-minute updates" via email

Sign up!

Send the E-mail Newsletter to a Colleague


Send

Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More

Close